Results 21 to 30 of about 2,839,497 (322)

An Automatic Motion-Based Artifact Reduction Algorithm for fNIRS in Concurrent Functional Magnetic Resonance Imaging Studies (AMARA–fMRI)

Algorithms, 2023
Multimodal functional near-infrared spectroscopy–functional magnetic resonance imaging (fNIRS–fMRI) studies have been highly beneficial for both the fNIRS and fMRI field as, for example, they shed light on the underlying mechanism of each method. However,
Lia Maria Hocke, Yunjie Tong, Blaise deBonneval Frederick   +2 more
doaj   +1 more source

Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a post-hoc Analysis

Frontiers in Medicine, 2022
Approximately 12–13% of patients with interstitial lung disease (ILD) are diagnosed with unclassifiable ILD (uILD), often despite thorough evaluation. A recent Phase 2 study (NCT03099187) described a significant effect of pirfenidone vs.
Maria Molina-Molina, Maria Molina-Molina, Michael Kreuter, Michael Kreuter, Vincent Cottin, Vincent Cottin, Tamera J. Corte, Tamera J. Corte, Frank Gilberg, Klaus-Uwe Kirchgaessler, Judit Axmann, Toby M. Maher, Toby M. Maher, Toby M. Maher   +13 more
doaj   +1 more source

Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

Annals of the Rheumatic Diseases, 2022
Objectives Evaluate risk of major adverse cardiovascular events (MACE) with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA) with or without a history of atherosclerotic cardiovascular disease (ASCVD)
C. Charles-Schoeman, M. Buch, M. Dougados, Deepak L. Bhatt, J. Giles, S. Ytterberg, G. Koch, I. Vranic, Joseph Wu, Cunshan Wang, K. Kwok, S. Menon, J. Rivas, A. Yndestad, C. Connell, Z. Szekanecz   +15 more
semanticscholar   +1 more source

Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial

Diabetes, obesity and metabolism, 2022
To perform a post hoc analysis of the FIGHT trial, evaluating the effect of liraglutide (vs. placebo) on the totality of events in patients with heart failure with reduced ejection fraction (HFrEF).
J. Neves, F. Vasques-Nóvoa, M. Borges-Canha, A. Leite, Abhinav Sharma, D. Carvalho, M. Packer, F. Zannad, A. Leite-Moreira, J. P. Ferreira   +9 more
semanticscholar   +1 more source

Microelement Variability in Plants as an Effect of Sewage Sludge Compost Application Assessed by Different Statistical Methods

Agronomy, 2020
This research deals with the effects of soil amendment with sewage sludge compost (SSC) on the accumulation of microelements (Cu, Zn, Mn, Ni, Fe) in plants—white mustard (Sinapis alba), triticale (Triticale) and white lupine (Lupinus albus)—cultivated on
Monika Jakubus, Małgorzata Graczyk
doaj   +1 more source

The number of risk factors not at target is associated with cardiovascular risk in a type 2 diabetic population with albuminuria in primary cardiovascular prevention. Post-hoc analysis of the NID-2 trial

Cardiovascular Diabetology, 2022
Background Nephropathy in Diabetes type 2 (NID-2) study is an open-label cluster randomized clinical trial that demonstrated that multifactorial intensive treatment reduces Major Adverse Cardiac Events (MACEs) and overall mortality versus standard of ...
F. C. Sasso, V. Simeon, R. Galiero, A. Caturano, L. De Nicola, P. Chiodini, L. Rinaldi, T. Salvatore, Miriam Lettieri, R. Nevola, C. Sardu, Giovanni Docimo, G. Loffredo, R. Marfella, L. Adinolfi, R. Minutolo, U C P O G G M R A L N E G A S L L A A A N S P V P R Amelia Acierno Calatola Carbonara Conte Corigliano, U. Amelia, C. Acierno, P. Calatola, O. Carbonara, G. Conte, G. Corigliano, M. Corigliano, R. D’Urso, A. De Matteo, L. De Nicola, N. De Rosa, E. Del Vecchio, G. di Giovanni, A. Gatti, S. Gentile, L. Gesuè, L. Improta, A. LampitellaJr, A. Lampitella, A. Lanzilli, N. Lascar, S. Masi, P. Mattei, V. Mastrilli, P. Memoli, R. Minutolo, R. Nasti, A. Pagano, M. Pentangelo, E. Pisa, E. Rossi, F. C. Sasso, S. Sorrentino, R. Torella, R. Troise, P. Trucillo, A. Turco, S. Turco, F. Zibella, L. Zirpoli   +56 more
semanticscholar   +1 more source

Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1–Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis

Journal of Clinical Oncology, 2022
PURPOSE Pembrolizumab or nivolumab plus chemotherapy was approved as a first-line treatment for high programmed cell death ligand 1 (PD-L1)–expressing esophageal squamous cell carcinoma (ESCC) by the European Medicines Agency, whereas the US Food and ...
Hao-xiang Wu, Yi Pan, Ye-Mei He, Zixian Wang, Wen-long Guan, Yanxing Chen, Yi-Chen Yao, Ningyi Shao, Ruifeng Xu, Feng Wang   +9 more
semanticscholar   +1 more source

Post-hoc analysis of Arabic transformer models

Proceedings of the Fifth BlackboxNLP Workshop on Analyzing and Interpreting Neural Networks for NLP, 2022
BlackboxNLP 2022.
Abdelali, Ahmed, Durrani, Nadir, Dalvi, Fahim, Sajjad, Hassan   +3 more
openaire   +2 more sources

The dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis

Diabetes, obesity and metabolism, 2021
In a phase 2 trial of once‐weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo, the dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide dose‐dependently reduced HbA1c and body ...
Jonathan M. Wilson, Yanzhu Lin, M. Jane Luo, Gary Considine, Amy L. Cox, Lenden M. Bowsman, D. Robins, A. Haupt, Kevin L. Duffin, G. Ruotolo   +9 more
semanticscholar   +1 more source

Metformin and N-terminal pro B-type natriuretic peptide in type 2 diabetes patients, a post-hoc analysis of a randomized controlled trial

PLoS ONE, 2021
Background Beyond antihyperglycemic effects, metformin may improve cardiovascular outcomes. Patients with type 2 diabetes often have an elevated plasma level of N-terminal pro B-type as a marker of (sub) clinical cardiovascular disease.
W. Top, P. Lehert, C. Schalkwijk, C. Stehouwer, A. Kooy   +4 more
semanticscholar   +1 more source